Takeda’s blood cancer drug fails to achieve Phase III endpoint
Pevonedistat plus azacitidine did not meet primary endpoint of EFS
Read More
Tag: pevonedistat
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
